Sector News

Pfizer megamergers? Bring 'em on, CEO says

June 6, 2016
Life sciences

Pfizer CEO Ian Read may be done trying for a tax inversion after his company’s $160 billion Allergan deal fell through. But he isn’t necessarily done trying for a megamerger.

Pfizer’s management team is open to any deals that will create value for shareholders, he said at the Sanford Bernstein Annual Strategic Decisions Conference, according to Bloomberg. And that leaves whopper acquisitions on the table.

“If you believe you can reorganize your research into productive smaller units, there is a logic to consolidation of the industry by taking out duplicative expenses,” especially if the two companies can squeeze out some serious savings, Read said, as quoted by the news service.

Pfizer has so far come up short in two straight megamerger attempts. Back in 2014, it struck out on a hostile pursuit of AstraZeneca, thanks to its target’s determination to keep flying solo. And earlier this year, new, stricter inversion rules from the U.S. Treasury scuttled its already agreed-upon Allergan transaction.

The way some industry-watchers see it, though, Pfizer would be better off if it didn’t try to swallow another larger drugmaker–which it’s done plenty of times, with buyouts of Wyeth, Warner-Lambert and Pharmacia in the rearview mirror.

“A company that needs repeated mega-acquisitions to keep afloat is inherently unsustainable,” Forbes’ Bernard Munos wrote late last year, noting that Pfizer’s revenue flattens or declines after spiking between major deals.

Meanwhile, Pfizer has jumped into the fray a couple times recently in search of smaller buys. Last month, it agreed to shell out $4.5 billion for California-based Anacor Pharmaceuticals, and rumor has it coveted target Medivation has opened its books to the pharma giant–much to the frustration of hostile bidder Sanofi.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach